Skip to content
Back to the Guavy Wire
Stocks

Moderna's Cancer Vaccine Shows Promise but Stock Drops

Instruments
MRK
Share

Moderna's experimental cancer vaccine, intismeran autogene, showed promising results in a Phase 3 trial, yet its stock plummeted more than 25% on October 22, 2026. The vaccine, developed in partnership with Merck, reduced the risk of recurrence or death by 42% when combined with Merck's Keytruda. However, investors had anticipated an even more impressive outcome, with some analysts expecting a hazard ratio below 0.60, which would have indicated a reduction in risk of more than 40%. The actual result came in at 0.58, narrowly clearing that threshold.

Despite the initial disappointment, a closer look at the full data presentation revealed more encouraging details. The vaccine demonstrated a 58% lower risk of recurrence or death after six months of treatment. Additionally, the safety profile was favorable, with serious treatment-related adverse events occurring in around 10% of patients receiving the Moderna-Merck combination, compared with 30% in a separate trial of Opdivo and Yervoy. This suggests that intismeran could be a viable option for patients who cannot tolerate more aggressive immunotherapy combinations.

The potential of intismeran extends beyond melanoma. Moderna and Merck are exploring its use in other cancers, including renal cell carcinoma, bladder cancer, and non-small cell lung cancer. Preliminary data from a study on pancreatic cancer showed that 55% of patients remained relapse-free after 17 months of follow-up. However, the vaccine still requires FDA approval, and its effectiveness in other cancer types has yet to be proven.

Moderna's stock trades at a price-to-sales ratio of about 35 times, reflecting high expectations for future growth. In contrast, Merck trades at a forward price-to-earnings ratio of about 16. Analysts suggest that investors may be overlooking the broader opportunity presented by Moderna's personalized mRNA technology, which could revolutionize cancer treatment if proven effective across different cancer types.

More on Stocks